You are here: Industry Insights > Market News > AstraZeneca Pharma India gets DCGI nod for benralizumab injection, Fasenra

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Jackfruit Powder

Pineapple Powder

Musang King Durian Powder

Noni Enzyme Powder

VITAMIN B12

hydraulic column packer/protein chromatography column/prepacked gel column packer

AstraZeneca Pharma India gets DCGI nod for benralizumab injection, Fasenra

expresspharmaDecember 22, 2020

Tag: AstraZeneca , DCGI , benralizumab , CT-20 , FASENRA

Favorites

AstraZeneca Pharma India has received Import and Market Permission in Form CT-20 (Marketing Authorisation) from the Drugs Controller General of India (DCGI) for Benralizumab 30mg/mL solution for injection (Fasenra).

Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.

The receipt of this permission paves way for the launch of Benralizumab (Fasenra) in India, subject to the receipt of related statutory approvals and licenses.

Previous:Sosei Heptares and GSK sign collaboration and license pact targeting GI immune disorders

Next:FDA investigates allergic reactions of Pfizer Covid-19 vaccine in US

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

PharmaSourcesMay 16, 2025

InnoCare Pharma announced today that the first patient has been dosed in the Phase II/III clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), for the treatment patients with non-segmental vitiligo in China.

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

PR NewswireMay 12, 2025

Illuccix China Phase 3 Study Completes Enrolment

PR NewswireMay 13, 2025

AstraZeneca Pharma India gets DCGI nod for benralizumab injection, Fasenra | Pharmasources.com

iotaMotion Announces First Use of Robotic-Assistedmpla Cochlear Int Technology Outside the U.S. as Part of Clinical Investigation in Switzerland

PR NewswireMay 14, 2025

iotaMotion, Inc., a leader in robotic-assisted systems for cochlear implant surgery, announced the first use of the iotaSOFT? Insertion System outside of the United States.

996热re视频精品视频这里,国产又色又爽又高潮免费,精品自拍亚洲一区在线,久久久综合九色合综,国产精品亚洲综合一区在线观看

AstraZeneca Pharma India gets DCGI nod for benralizumab injection, Fasenra

Related News

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

Illuccix China Phase 3 Study Completes Enrolment

iotaMotion Announces First Use of Robotic-Assistedmpla Cochlear Int Technology Outside the U.S. as Part of Clinical Investigation in Switzerland

You may like
More>>

996热re视频精品视频这里,国产又色又爽又高潮免费,精品自拍亚洲一区在线,久久久综合九色合综,国产精品亚洲综合一区在线观看

AstraZeneca Pharma India gets DCGI nod for benralizumab injection, Fasenra

Related News

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

Illuccix China Phase 3 Study Completes Enrolment

iotaMotion Announces First Use of Robotic-Assistedmpla Cochlear Int Technology Outside the U.S. as Part of Clinical Investigation in Switzerland

You may likeMore>>

You may like
More>>